A team of University of Wisconsin–Madison scientists has developed the first 3D-printed brain tissue that can grow and function like typical brain tissue.
Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease, and retinitis pigmentosa all have different manifestations and affect different body functions, but they are all connected by one mechanism: neurodegeneration.
Researchers a have identified a protein key to the development of a type of brain cell believed to play a role in disorders like Alzheimer’s and Parkinson’s diseases and used the discovery to grow the neurons from stem cells for the first time.
Allison and Amber Westemeier get excited every time they take a trip to the Waisman Center from Oshkosh, WI.
The extent to which amyloid-β burden and neurofibrillary tau tangle burden are associated with synaptic degeneration in vivo is not well known.
White matter (WM) degeneration is a critical component of early Alzheimer’s disease (AD) pathophysiology.
Unintentional weight loss in people with Down syndrome may predict the onset of Alzheimer’s disease long before typical cognitive symptoms like memory loss and dementia are apparent.
Individuals with Down syndrome are at higher risk of developing Alzheimer’s disease, and it typically presents it at an earlier age than the general population. It is estimated that 90% of people with Down syndrome will have developed Alzheimer’s by age 65.
People with Down Syndrome (DS) are at high risk for Alzheimer’s disease (AD) because of their unique biology and provide an unparalleled opportunity to develop biomarkers of preclinical AD.
Insulin resistance (IR) has been related to reduced cerebral glucose metabolism in regions identified as hypometabolic in Alzheimer’s clinical syndrome. Insulin secretion (IS) has been less studied than IR despite findings that decreased IS is an early indicator of future type 2 diabetes and a potential predictor of Alzheimer’s clinical syndrome.